Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial
Brief Summary: Improving adherence to inhaled corticosteroids (ICS) medication in urban minority pediatric populations is a clinical and population health priority. Financial incentives have been shown as a compelling method to engage a high-risk asthma population in regular ICS use, but whether and how adherence can be maintained and lead to sustained high adherence trajectories is unknown.


Options:
A: Inclusion Criteria:

* Patients prescribed therapy equivalent to step 3 or higher on the Asthma Management Guidelines for at least 3 months
* At least one exacerbation in the previous year with systemic glucocorticoids
* Uncontrolled/Partially Controlled Asthma by GINA guidelines

Exclusion Criteria:

* Allergy to salmeterol/fluticasone
* Patients Controlled by GINA guidelines
B: Inclusion Criteria:

* English-speaking individuals between 15-21
* Persistent asthma (diagnosis made by a healthcare provider)
* On a daily controller medication
* Able to give informed consent
* Smartphone (iOS or Android) access

Exclusion Criteria:

* Use of oral corticosteroids in the 2 weeks prior to the baseline visit
* Pregnancy
* Severe psychiatric or cognitive problems that would prohibit an individual from understanding and completing the protocol
* Patients that previously received the ASTHMA-Educator application
C: Inclusion Criteria:

* Males or females age 5 to 12 years and their parent or legal guardian.
* Caregiver has an app enabled cellular phone (i.e., smart phone)
* Prescribed inhaled corticosteroid or corticosteroid/long acting beta agonist combination for daily use
* At least 2 asthma exacerbations in the preceding year (Any combination of hospitalizations, ED visits, or outpatient visits where oral steroid courses were administered for asthma)
* Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria:

* Subjects prescribed a controller medication to which the electronic device cannot affix
* Subjects in which the mobile app is not compatible with their smart phone model
* Subjects with major developmental delays or disabilities
* Subjects with comorbid chronic diagnoses that influence their asthma management such as cystic fibrosis, bronchopulmonary dysplasia, or cyanotic heart disease
* Families with active Department of Human Services (DHS) involvement
* Non-English speaking families
* Parents/guardians or subjects whose medical team recommends against approaching for enrollment in a research study.
D: Inclusion Criteria:

* Doctor diagnosed asthma.
* On at least BTS stage 2, which means they will be on regular inhaled steroids.
* No change in regular asthma treatment in the last 1 month (on regular inhaled steroids, no change in steroid dose for

  1 month, no change in add on therapy in the last month).
* ACQ (Asthma Control Questionnaire) score more than or equal to 1.5.
* Can speak and understand English.

Exclusion Criteria:

* BTS stage 5 asthma (complex issues, too unstable).
* Recent changes to asthma treatment within the last month. (see above)
* ACQ (Asthma Control Questionnaire) score \< 1.5.
* Another chronic health condition (eg diabetes, congenital heart disease, cystic fibrosis).
* Can't speak or understand English.

Answer: C